Effect of monotherapy and combination therapy of pantoprazole and aprepitant in gastric esophageal reflux disease in albino rats.
The present study was undertaken to elucidate the effect of pantoprazole and aprepitant on experimental esophagitis in albino rats. Groups of rats, fasted overnight, received normal saline (3 mL/kg, sham control) or toxic control (3 mL/kg) or pantoprazole (30 mg/kg) or aprepitant (10 mg/kg), or their combinations and were subjected to pylorus and forestomach ligation. Animals were sacrificed after 8 h and evaluated for the gastric pH, volume of gastric juices, total acidity, esophagitis index, and free acidity. Esophageal tissues were further subjected to estimations of TBARS, GSH, catalase, and SOD. Treatment with pantoprazole and aprepitant significantly inhibited the gastric secretion, total acidity, and esophagitis index. The treatment also helped to restore the altered levels oxidative stress parameters to normal.
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Vidya Vihar, Raebareli Road, Lucknow 226 025, India.
Kamleshwar
K
Shukla
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Vidya Vihar, Raebareli Road, Lucknow 226 025, India.
Prince
P
Raj
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Vidya Vihar, Raebareli Road, Lucknow 226 025, India.
Arun
A
Kumar
Department of Applied Animal Sciences, Babasaheb Bhimrao Ambedkar University, Vidya Vihar, Raebareli Road, Lucknow 226 025, India.
Mukesh
M
Kumar
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Vidya Vihar, Raebareli Road, Lucknow 226 025, India.
Gaurav
G
Kaithwas
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000077608:Aprepitant; D002374:Catalase / Q000378:metabolism; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005978:Glutathione / Q000097:blood; D009025:Morpholines / Q000008:administration & dosage / Q000494:pharmacology*; D064729:Neurokinin-1 Receptor Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D013482:Superoxide Dismutase / Q000097:blood; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D054328:Proton Pump Inhibitors; D017392:Thiobarbituric Acid Reactive Substances; D000077608:Aprepitant; D000077402:Pantoprazole; D002374:Catalase; D013482:Superoxide Dismutase; D005978:Glutathione